Engineered microbes are rapidly being developed for the delivery of therapeutic modalities to sites of disease. Escherichia coli Nissle 1917 (EcN), a genetically tractable probiotic with a well-established human safety record, is emerging as a favored chassis. Here, we summarize the latest progress in rationally engineered variants of EcN for the treatment of infectious diseases, metabolic Jan 25, 2022 · The objective of the present study was to investigate the beneficial effect of genetically modified Escherichia coli Nissle 1917 (EcN-GM) in obese C57BL/6J mice. First, an obesity model in C57BL Sep 14, 2021 · The programmable engineering platform is further developed for the controlled and effective colonization of Escherichia coli Nissle 1917 (EcN) in the gut. The colonizing bacteria effectively alleviate DSS-induced colitis in mice. Apr 1, 2004 · We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis. Patients and methods: In total, 327 patients were recruited and assigned to a double blind, double dummy trial to receive either the probiotic drug 200 mg once Aug 22, 2017 · Campylobacter jejuni is a leading cause of bacterial food poisoning in humans. Due to the rise in antibiotic-resistant Campylobacter, there exists a need to develop antibiotic-independent interventions to control infections in humans. Here, we evaluated the impact of Escherichia coli Nissle 1917 (EcN), a probiotic strain, on C. jejuni’s invasion and intracellular survival in polarized human Jan 1, 2021 · Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium originally isolated from a particularly healthy soldier from World War I by the physician Alfred Nissle. 1 Since then, this bacterium has found significant use as a probiotic therapy, outcompeting pathogens in the gut 2 and thus protecting the host from infection. .

e coli nissle 1917 probiotyk